Condition
End-stage Liver Disease (ESLD)
Total Trials
4
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07442214Active Not RecruitingPrimary
View of Cerebral Perfusion in Liver Transplantation
NCT06823713Phase 1RecruitingPrimary
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT07157631Not ApplicableRecruiting
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
NCT02776553Not ApplicableCompletedPrimary
A Physical Activity Program in End-state Liver Disease
Showing all 4 trials